<REFSHEAD> References
<REFS>1. Kozik DJ, Tweddell JS. Characterizing the inflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg 2006;81:S2347–54.
2. Sonntag J, Dahnert I, Stiller B, et al. Complement and contact activation during cardiovascular operations in infants. Ann Thorac Surg 1998;65:525–31.
3. Chew MS, Brandslund I, Brix-Christensen V, et al. Tissue injury and the inflammatory response to pediatric cardiac surgery with cardiopulmonary bypass: a descriptive study. Anesthesiology 2001;94:745–53; discussion 5A.
4. Duval EL, Kavelaars A, Veenhuizen L, van Vught AJ, et al. Pro- and anti-inflammatory cytokine patterns during and after cardiac surgery in young children. Eur J Pediatr 1999;158:387–93.
5. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;106:1008–16.
6. Seghaye MC, Duchateau J, Grabitz RG, et al. Complement activation during cardiopulmonary bypass in infants and children. Relation to postoperative multiple system organ failure. J Thorac Cardiovasc Surg 1993;106:978–87.
7. Seghaye MC, Duchateau J, Grabitz RG, et al. Complement, leukocytes, and leukocyte elastase in full-term neonates undergoing cardiac operation. J Thorac Cardiovasc Surg 1994;108:29–36.
8. Jaggers JJ, Neal MC, Smith PK, et al. Infant cardiopulmonary bypass: a procoagulant state. Ann Thorac Surg 1999;68:513–20.
9. Felps W, Mitchell TR, Byington E. How, when, and why bad apples spoil the barrel: negative group members and dysfunctional groups. Res Org Behav 2006;27:175–222.
10. Edelson MB, Bagwell CE, Rozycki HJ. Circulating pro- and counterinflammatory cytokine levels and severity in necrotizing enterocolitis. Pediatrics 1999;103:766–71.
11. Lequier LL, Nikaidoh H, Leonard SR, et al. Preoperative and postoperative endotoxemia in children with congenital heart disease. Chest 2000;117:1706–12.
12. Mollhoff T, Loick HM, Van Aken H, et al. Milrinone modulates endotoxemia, systemic inflammation, and subsequent acute phase response after cardiopulmonary bypass (CPB). Anesthesiology 1999;90:72–80.
13. Gercekoglu H, Tarim O, Agar I, , et al. Effects of hypothermia on blood endogenous endotoxin levels during cardiopulmonary bypass. J Card Surg 1997;12:223–7.
14. Pearl JM, Manning PB, McNamara JL, et al. Effect of modified ultrafiltration on plasma thromboxane B2, leukotriene B4, and endothelin-1 in infants undergoing cardiopulmonary bypass. Ann Thorac Surg 1999;68:1369–75.
15. Patel NN, Toth T, Jones C, et al. Prevention of post-cardiopulmonary bypass acute kidney injury by endothelin A receptor blockade. Crit Care Med 2011;39:793–802.
16. Komai H, Haworth SG. Effect of cardiopulmonary bypass on the circulating level of soluble GMP-140. Ann Thorac Surg 1994;58:478–82.
17. Schwinn DA, Leone BJ, Spahn DR, , et al. Desensitization of myocardial beta-adrenergic receptors during cardiopulmonary bypass. Evidence for early uncoupling and late downregulation. Circulation 1991;84:2559–67.
18. Shinkawa T, Anagnostopoulos PV, Johnson NC, Presnell L, Watanabe N, Sapru A, et al. Early results of the "clamp and sew" Fontan procedure without the use of circulatory support. Ann Thorac Surg 2011;91:1453–9.
19. Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387–9.
20. Lodge AJ, Chai PJ, Daggett CW, et al. Methylprednisolone reduces the inflammatory response to cardiopulmonary bypass in neonatal piglets: timing of dose is important. J Thorac Cardiovasc Surg 1999;117:515–22.
21. Graham EM, Atz AM, McHugh KE, et al. Preoperative steroid treatment does not improve markers of inflammation after cardiac surgery in neonates: Results from a randomized trial. J Thorac Cardiovasc Surg 2014;147:902–8.
22. Graham EM, Atz AM, Butts RJ, et al. Standardized preoperative corticosteroid treatment in neonates undergoing cardiac surgery: results from a randomized trial. J Thorac Cardiovasc Surg 2011;142:1523–9.
23. Pasquali SK, Li JS, He X, et al. Perioperative methylprednisolone and outcome in neonates undergoing heart surgery. Pediatrics 2012;129:e385–91.
24. Keski-Nisula J, Pesonen E, Olkkola KT, et al. Methylprednisolone in neonatal cardiac surgery: reduced inflammation without improved clinical outcome. Ann Thorac Surg 2013;95:2126–32.
25. Allan CK, Newburger JW, McGrath E, et al. The relationship between inflammatory activation and clinical outcome after infant cardiopulmonary bypass. Anesth Analg 2010;111:1244–51.
26. Journois D, Pouard P, Greeley WJ, et al. Hemofiltration during cardiopulmonary bypass in pediatric cardiac surgery. Effects on hemostasis, cytokines, and complement components. Anesthesiology 1994;81:1181–9.
27. Naik SK, Knight A, Elliott MJ. A successful modification of ultrafiltration for cardiopulmonary bypass in children. Perfusion 1991;6:41–50.
28. Atkins BZ, Danielson DS, Fitzpatrick CM, et al. Modified ultrafiltration attenuates pulmonary-derived inflammatory mediators in response to cardiopulmonary bypass. Interact Cardiovasc Thorac Surg 2010;11:599–603.
29. Hennein HA, Kiziltepe U, Barst S, et al. Venovenous modified ultrafiltration after cardiopulmonary bypass in children: a prospective randomized study. J Thorac Cardiovasc Surg 1999;117:496–505.
30. Wang MJ, Chiu IS, Hsu CM, et al. Efficacy of ultrafiltration in removing inflammatory mediators during pediatric cardiac operations. Ann Thorac Surg 1996;61:651–6.
31. Harvey B, Shann KG, Fitzgerald D, et al. International pediatric perfusion practice: 2011 survey results. J Extra Corpor Technol 2012;44:186–93.
32. Bando K, Turrentine MW, Vijay P, et al. Effect of modified ultrafiltration in high-risk patients undergoing operations for congenital heart disease. Ann Thorac Surg 1998;66:821–7; discussion 8.
33. Carter J, Buerke U, Rossner E, , et al. Anti-inflammatory actions of aprotinin provide dose-dependent cardioprotection from reperfusion injury. Br J Pharmacol 2008;155:93–102.
34. Greilich PE, Brouse CF, Whitten CW, et al. Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin. J Thorac Cardiovasc Surg 2003;126:1498–503.
35. D'Errico CC, Shayevitz JR, Martindale SJ, et al. The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. Anesth Analg 1996;83:1193–9.
36. Miller BE, Tosone SR, Tam VK, et al. Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. Ann Thorac Surg 1998;66:535–40; discussion 41.
37. Mossinger H, Dietrich W, Braun SL, et al. High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery. Ann Thorac Surg 2003;75:430–7.
38. Later AF, Sitniakowsky LS, van Hilten JA, et al. Antifibrinolytics attenuate inflammatory gene expression after cardiac surgery. J Thorac Cardiovasc Surg 2013;145:1611–6, 6.e1–4.
39. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319–31.
40. Henry D, Carless P, Fergusson D, Laupacis A. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ 2009;180:183–93.
41. Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. J Am Med Assoc 2007;297:471–9.
42. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353–65.
43. Guzzetta NA, Evans FM, Rosenberg ES, et al. The impact of aprotinin on postoperative renal dysfunction in neonates undergoing cardiopulmonary bypass: a retrospective analysis. Anesth Analg 2009;108:448–55.
44. Backer CL, Kelle AM, Stewart RD, et al. Aprotinin is safe in pediatric patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2007;134:1421–6; discussion 6–8.
45. Szekely A, Sapi E, Breuer T, et al. Aprotinin and renal dysfunction after pediatric cardiac surgery. Paediatr Anaesth 2008;18:151–9.
46. Leyvi G, Nelson O, Yedlin A, et al. A comparison of the effect of aprotinin and epsilon-aminocaproic acid on renal function in children undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2011;25:402–6.
47. Ishihara K, Oshida H, Endo Y, et al. Hemocompatibility of human whole blood on polymers with a phospholipid polar group and its mechanism. J Biomed Mater Res.1992;26:1543–52.
48. Aldea GS, Soltow LO, Chandler WL, et al. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J Thorac Cardiovasc Surg 2002;123:742–55.
49. Mahmood S, Bilal H, Zaman M, Tang A. Is a fully heparin-bonded cardiopulmonary bypass circuit superior to a standard cardiopulmonary bypass circuit? Interact Cardiovasc Thorac Surg 2012;14:406–14.
50. Mangoush O, Purkayastha S, Haj-Yahia S, et al. Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes. Eur J Cardiothorac Surg 2007;31:1058–69.
51. Tuinman PR, Vlaar AP, Cornet AD, et al. Blood transfusion during cardiac surgery is associated with inflammation and coagulation in the lung: a case control study. Crit Care 2011;15:R59.
52. Gunaydin S, McCusker K, Vijay V. Perioperative blood conservation strategies in pediatric patients undergoing open-heart surgery: impact of non-autologous blood transfusion and surface-coated extracorporeal circuits. Perfusion 2011;26:199–205.
53. Despotis GJ, Zhang L, Lublin DM. Transfusion risks and transfusion-related pro-inflammatory responses. Hematol Oncol Clin North Am 2007;21:147–61.
54. Iyengar A, Scipione CN, Sheth P, et al. Association of complications with blood transfusions in pediatric cardiac surgery patients. Ann Thorac Surg 2013;96:910–6.
55. Szekely A, Cserep Z, Sapi E, et al. Risks and predictors of blood transfusion in pediatric patients undergoing open heart operations. Ann Thorac Surg 2009;87:187–97.
56. Guzzetta NA. Benefits and risks of red blood cell transfusion in pediatric patients undergoing cardiac surgery. Paediatr Anaesth 2010;21:504–11.
57. Hickey E, Karamlou T, You J, Ungerleider RM. Effects of circuit miniaturization in reducing inflammatory response to infant cardiopulmonary bypass by elimination of allogeneic blood products. Ann Thorac Surg 2006;81:S2367–72.
58. Arnold P. Treatment and monitoring of coagulation abnormalities in children undergoing heart surgery. Paediatr Anaesth 2011;21:494–503.
59. Miller BE, Mochizuki T, Levy JH, et al. Predicting and treating coagulopathies after cardiopulmonary bypass in children. Anesth Analg 1997;85:1196–202.
60. Guay J, Rivard GE. Mediastinal bleeding after cardiopulmonary bypass in pediatric patients. Ann Thorac Surg 1996;62:1955–60.
61. Williams GD, Bratton SL, Nielsen NJ, Ramamoorthy C. Fibrinolysis in pediatric patients undergoing cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1998;12:633–8.
62. Williams GD, Bratton SL, Riley EC, Ramamoorthy C. Association between age and blood loss in children undergoing open heart operations. Ann Thorac Surg 1998;66:870–5; discussion 5–6.
63. Balling G, Vogt M, Kaemmerer H, et al. Intracardiac thrombus formation after the Fontan operation. J Thorac Cardiovasc Surg 2000;119:745–52.
64. Cholette JM, Rubenstein JS, Alfieris GM, et al. Elevated risk of thrombosis in neonates undergoing initial palliative cardiac surgery. Ann Thorac Surg 2007;84:1320–5.
65. Gurgey A, Balta G, Gumruk F, Altay C. Analysis of some clinical and laboratory aspects of adolescent patients with thrombosis. Blood Coagul Fibrinolysis 2004;15:657–62.
66. Li JS, Yow E, Berezny KY, et al. Clinical outcomes of palliative surgery including a systemic-to-pulmonary artery shunt in infants with cyanotic congenital heart disease: does aspirin make a difference? Circulation 2007;116:293–7.
67. Monagle P. Thrombosis in pediatric cardiac patients. Semin Thromb Hemost 2003;29:547–55.
68. Dobell AR, Trusler GA, Smallhorn JF, Williams WG. Atrial thrombi after the Fontan operation. Ann Thorac Surg 1986;42:664–7.
69. Jahangiri M, Shore D, Kakkar V, et al. Coagulation factor abnormalities after the Fontan procedure and its modifications. J Thorac Cardiovasc Surg 1997;113:989–92; discussion 92–3.
70. Ong BC, Zimmerman AA, Zappulla DC, et al. Prevalence of factor V Leiden in a population of patients with congenital heart disease. Can J Anaesth 1998;45:1176–80.
71. Corrigan JJ, Jr., Jeter MA. Tissue-type plasminogen activator, plasminogen activator inhibitor, and histidine-rich glycoproteins in stressed human newborns. Pediatrics 1992;89:43–6.
72. Petaja J, Lundstrom U, Sairanen H, et al. Central venous thrombosis after cardiac operations in children. J Thorac Cardiovasc Surg 1996;112:883–9.
73. Petaja J, Peltola K, Sairanen H, et al. Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations. J Thorac Cardiovasc Surg 1996;112:665–71.
74. Attard C, van der Straaten T, Karlaftis V, et al. Developmental hemostasis: age-specific differences in the levels of hemostatic proteins. J Thromb Haemost 2013;11:1850–4.
75. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990;12:95–104.
76. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987;70:165–72.
77. Pichler E, Pichler L. The neonatal coagulation system and the vitamin K deficiency bleeding - a mini review. Wien Med Wochenschr 2008;158:385–95.
78. Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995;74:415–25.
79. Ignjatovic V, Ilhan A, Monagle P. Evidence for age-related differences in human fibrinogen. Blood Coagul Fibrinolysis 2011;22:110–7.
80. Grieninger G, Lu X, Cao Y, et al. Fib420, the novel fibrinogen subclass: newborn levels are higher than adult. Blood 1997;90:2609–14.
81. Ekert H, Gilchrist GS, Stanton R, Hammond D. Hemostasis in cyanotic congenital heart disease. J Pediatr 1970;76:221–30.
82. Ferencz C, Boughman JA, Neill CA, et al. Congenital cardiovascular malformations: questions on inheritance. Baltimore-Washington Infant Study Group. J Am Coll Cardiol 1989;14:756–63.
83. Ferencz C, Rubin JD, McCarter RJ, , et al. Hematologic disorders and congenital cardiovascular malformations: converging lines of research. J Med 1984;15:337–54.
84. Sharland M, Patton MA, Talbot S, et al. Coagulation-factor deficiencies and abnormal bleeding in Noonan's syndrome [see comments]. Lancet 1992;339:19–21.
85. Gill JC, Wilson AD, Endres-Brooks J, Montgomery RR. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood 1986;67:758–61.
86. Veldman A, Nold MF, Michel-Behnke I. Thrombosis in the critically ill neonate: incidence, diagnosis, and management. Vasc Health Risk Manag 2008;4:1337–48.
87. Cheung YF, Chay GW, Ma ES. Ethnic differences in coagulation factor abnormalities after the Fontan procedure. Pediatr Cardiol2006;27:96–101.
88. Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 2004;30:1873–81.
89. Eaton MP, Iannoli EM. Coagulation considerations for infants and children undergoing cardiopulmonary bypass. Paediatr Anaesth 2010;21:31–42.
90. Chan AK, Leaker M, Burrows FA, et al. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemost 1997;77:270–7.
91. Moganasundram S, Hunt BJ, Sykes K, , et al. The relationship among thromboelastography, hemostatic variables, and bleeding after cardiopulmonary bypass surgery in children. Anesth Analg 2010;110:995–1002.
92. Boldt J, Knothe C, Zickmann B, et al. Aprotinin in pediatric cardiac operations: platelet function, blood loss, and use of homologous blood. Ann Thorac Surg 1993;55:1460–6.
93. Boldt J, Knothe C, Zickmann B, et al. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations. Influence on platelet function and blood loss [see comments]. J Thorac Cardiovasc Surg 1993;105:705–11.